PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NVAX vs. AZN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NVAX and AZN is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

NVAX vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-38.42%
-14.47%
NVAX
AZN

Key characteristics

Sharpe Ratio

NVAX:

0.67

AZN:

0.08

Sortino Ratio

NVAX:

2.40

AZN:

0.24

Omega Ratio

NVAX:

1.30

AZN:

1.03

Calmar Ratio

NVAX:

0.98

AZN:

0.06

Martin Ratio

NVAX:

2.53

AZN:

0.13

Ulcer Index

NVAX:

38.12%

AZN:

12.11%

Daily Std Dev

NVAX:

143.50%

AZN:

20.65%

Max Drawdown

NVAX:

-98.82%

AZN:

-48.94%

Current Drawdown

NVAX:

-97.33%

AZN:

-23.64%

Fundamentals

Market Cap

NVAX:

$1.37B

AZN:

$203.68B

EPS

NVAX:

-$2.18

AZN:

$2.08

PEG Ratio

NVAX:

0.00

AZN:

0.71

Total Revenue (TTM)

NVAX:

$593.85M

AZN:

$39.18B

Gross Profit (TTM)

NVAX:

$448.38M

AZN:

$31.70B

EBITDA (TTM)

NVAX:

-$54.57M

AZN:

$12.79B

Returns By Period

In the year-to-date period, NVAX achieves a 6.09% return, which is significantly higher than AZN's 2.12% return. Over the past 10 years, NVAX has underperformed AZN with an annualized return of -24.24%, while AZN has yielded a comparatively higher 9.91% annualized return.


NVAX

YTD

6.09%

1M

-5.22%

6M

-42.98%

1Y

102.85%

5Y*

8.27%

10Y*

-24.24%

AZN

YTD

2.12%

1M

-0.40%

6M

-13.76%

1Y

3.18%

5Y*

8.05%

10Y*

9.91%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NVAX vs. AZN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVAX
The Risk-Adjusted Performance Rank of NVAX is 7878
Overall Rank
The Sharpe Ratio Rank of NVAX is 7070
Sharpe Ratio Rank
The Sortino Ratio Rank of NVAX is 8686
Sortino Ratio Rank
The Omega Ratio Rank of NVAX is 8484
Omega Ratio Rank
The Calmar Ratio Rank of NVAX is 7979
Calmar Ratio Rank
The Martin Ratio Rank of NVAX is 7171
Martin Ratio Rank

AZN
The Risk-Adjusted Performance Rank of AZN is 4646
Overall Rank
The Sharpe Ratio Rank of AZN is 5050
Sharpe Ratio Rank
The Sortino Ratio Rank of AZN is 4141
Sortino Ratio Rank
The Omega Ratio Rank of AZN is 4040
Omega Ratio Rank
The Calmar Ratio Rank of AZN is 5050
Calmar Ratio Rank
The Martin Ratio Rank of AZN is 4949
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NVAX vs. AZN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NVAX, currently valued at 0.67, compared to the broader market-2.000.002.004.000.670.08
The chart of Sortino ratio for NVAX, currently valued at 2.40, compared to the broader market-4.00-2.000.002.004.002.400.24
The chart of Omega ratio for NVAX, currently valued at 1.30, compared to the broader market0.501.001.502.001.301.03
The chart of Calmar ratio for NVAX, currently valued at 0.98, compared to the broader market0.002.004.006.000.980.06
The chart of Martin ratio for NVAX, currently valued at 2.53, compared to the broader market-10.000.0010.0020.0030.002.530.13
NVAX
AZN

The current NVAX Sharpe Ratio is 0.67, which is higher than the AZN Sharpe Ratio of 0.08. The chart below compares the historical Sharpe Ratios of NVAX and AZN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
0.67
0.08
NVAX
AZN

Dividends

NVAX vs. AZN - Dividend Comparison

NVAX has not paid dividends to shareholders, while AZN's dividend yield for the trailing twelve months is around 2.22%.


TTM20242023202220212020201920182017201620152014
NVAX
Novavax, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AZN
AstraZeneca PLC
2.22%2.27%2.15%2.14%2.40%2.80%2.81%3.61%3.95%5.01%4.06%3.98%

Drawdowns

NVAX vs. AZN - Drawdown Comparison

The maximum NVAX drawdown since its inception was -98.82%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVAX and AZN. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-97.33%
-23.64%
NVAX
AZN

Volatility

NVAX vs. AZN - Volatility Comparison

Novavax, Inc. (NVAX) has a higher volatility of 23.41% compared to AstraZeneca PLC (AZN) at 5.99%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
23.41%
5.99%
NVAX
AZN

Financials

NVAX vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Novavax, Inc. and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab